CAI — Caris Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $5.20bn
- $4.78bn
- $812.03m
Annual income statement for Caris Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 306 | 412 | 812 |
| Cost of Revenue | |||
| Gross Profit | 91.3 | 180 | 541 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 637 | 669 | 787 |
| Operating Profit | -330 | -257 | 25.2 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -341 | -282 | -68.1 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -341 | -282 | -68.1 |
| Net Income Before Extraordinary Items | |||
| Net Income | -341 | -282 | -68.1 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -463 | -378 | -538 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -1.62 | -1.36 | -3.1 |